CHMP disregards PRAC call to suspend Servier's Protelos in EU
This article was originally published in Scrip
The European Medicines Agency says that Servier's osteoporosis treatment Protelos/Osseor (strontium ranelate) should remain on the market with additional restrictions, even though its Pharmacovigilance Risk Assessment Committee (PRAC) recommended in January that the product should be suspended.
You may also be interested in...
A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded.
The health technology assessment bodies for England and Scotland have this week issued positive recommendations on the funding of several innovative new medicines on the National Health Service, including products for myeloma, kidney cancer and multiple sclerosis.
Proposals from NICE that are out for consultation are intended to boost the HTA body’s efficiency, improve transparency and governance, and raise the quality of its guidance.